Lead Product(s): Metalloenzyme-targeted medicines
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 08, 2021
Blacksmith and Lilly will collaborate on up to 5 human metalloenzyme targets, with Blacksmith advancing novel small molecule inhibitors from fragment to 'hit' stage after which Lilly has the right to continue research, development, and commercialization.